General

Meet us at the 11th German-Austrian AIDS Congress (DÖAK 2023) Sehen wir uns beim #DÖAK? Vom 23. bis 25. März 2023 sind wir beim 11. Deutsch-Österreichischen AIDS-Kongress in Bonn! Besuchen Sie uns am Stand und freuen Sie sich auf drei Kongresstage mit einem umfangreichen Programm auf dem höchsten Stand der wissenschaftlichen Forschung.Unter dem Motto „HIV und […]

New Scientific Publication: From Capillary Electrophoresis to Deep Sequencing: An Improved HIV-1 Drug Resistance Assessment Solution Using In Vitro Diagnostic (IVD) Assays and Software We are pleased to share the release of our peer-reviewed article detailing the performances of the DeepChek® solution, reagents and software, which helps virologists and clinicians assessing HIV-1 Drug Resistance (HDR)

Strengthening the historic partnership with Roche diagnostics Spain to extend the offer to the Spanish market ABL Diagnostics, the leading provider of genotyping diagnostic tests for infectious diseases, herewith announces that in early December it signed an agreement with Roche Diagnostics Spain to strengthen its position as a leader in HIV genotyping in Spain and

Web TV Interview: ABL Diagnostics fait le point sur son activité We are happy to share our first webTV interview during which we have explained ABL Diagnostics activity and the development of our market. Co-founders of ABL Group: Dr Sayada & M. Boulmé talked about the original IPO via a reverse take over and they

Interest of HIV-1 Next-Generation Sequencing in a diagnosis laboratory in France The objective of this study consists in the analyse  the interest of HIV NGS sequencing, targeted , protease (PR), reverse transcriptase (RT), integrase (INT) and V3 loop or of the complete genome at the virology department of the University Hospital of Caen and the

ABL Diagnostics increases its production capacities and its resilience thanks to the “France Relance” program ABL Diagnostics is pleased to announce that a substantial increase of its molecular assays production capacities has been allowed thanks to the RESILIENCE France Relance program entitled “SOUTIEN A L’INVESTISSEMENT ET LA MODERNISATION DE L’INDUSTRIE“.  In the context of the

ABL Diagnostics signed a Channel Partner Agreement with Illumina to offer, combined with ABL Diagnostics’ DeepChek™ products, on the iSeq™ 100 and MiSeq™ next-generation sequencing platforms to microbiology laboratories in mainland France Belgium and Luxembourg ABL Diagnostics is pleased to announce a strategic collaboration with Illumina through an international Channel Partners Agreement conferring to ABL

Meet us at MEDICA 2022 Meet us at MEDICA 2022 and Discover our Microbiology Genotyping SolutionsABL will be attending the next MEDICA forum in Düsseldorf from 14 – 17 November 2022 (Luxembourg Ministry of Economy – Hall 3 / A74).  Please come by our booth. We will introduce you our 360° expertise in molecular diagnostics and genotyping by

ABL Diagnostics sponsored the NTDD Symposium in Utrecht (NL) ABL Diagnostics sponsored the NTDD Symposium in Utrecht and presented the DeepChek® kit for Tuberculosis Genotyping & Drug Resistance through NGS sequencing 🧬. Our Sales representatives Vito Grasso and Joffrey BIGNOUNGA had the opportunity to meet the very kind Dutch TB community.

Set up of New Generation Sequencing (NGS) for the detection of Ganciclovir Resistance in the Molecular Biology Laboratory of the Hospital de Clínicas. We would like to thank our local representative in Uruguay Biko which is our local representative in Uruguay and Molecular Biology Laboratory of the Hospital de Clínicas for highlighting our CMV genotyping